Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13968294 | 0.86 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL410217 | 0.81 | RET (0.40) | — | |
| SCHEMBL22037087 | 0.79 | — | — | |
| SCHEMBL20371382 | 0.76 | — | — | |
| SCHEMBL10260070 | 0.75 | RET (0.40) | ALDH1A1 | |
| SCHEMBL27439393 | 0.72 | — | — | |
| SCHEMBL19235026 | 0.69 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL13968297 | 0.69 | CCNT1 (0.31) | — | |
| SCHEMBL13077692 | 0.68 | RET (0.40) | — | |
| SCHEMBL19476929 | 0.67 | RET (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200055859-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289515-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | ALDH1A1 4521/4885EGLN2 2618/4885 |
| US-20200055859-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | ABL1, BTK, ABL2 | ALDH1A1 4019/4885EGLN2 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.